Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

Reported by Yahoo Finance · Published 31 Jul 2026, 5:58 AM MYT (1 d ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

How bitcoin cold wallets lost $70 million in an attack that never touched the devices 18 min ago US Treasury intervenes to support yen after Japan steps in 4 hr ago US Treasury intervenes to support yen after Japan steps in, FT reports 5 hr ago US bars imports from more Chinese firms over alleged Uyghur forced labour 5 hr ago With Situational Awareness AI deal, Citadel's Griffin rides to the rescue again 6 hr ago OpenAI says has more than 1 billion active users 6 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

Summary

More in Markets

July ends on a hopeful note for stocks after momentum trade sees biggest wipeout since 2000

Situational Awareness vs. Long-Term Capital Management: A side-by-side comparison

The S&P 500 is making a change by adding this little-known industrial stock

Did China build a top-tier AI model by itself? A new report suggests Nvidia chips played a role.

Want to trade SpaceX for Apple? 1inch says skip the dollars

We’re in our 60s with $1.5 million. Would a trust be more effective than a will to prevent conflict among our heirs?